These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 9819098)

  • 1. Low-density lipoproteins and risk for coronary artery disease.
    Ballantyne CM
    Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low density lipoprotein cholesterol: is lower better?
    Leiter LA
    Can J Cardiol; 2000 Jan; 16 Suppl A():20A-2A. PubMed ID: 10653927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low density lipoprotein cholesterol lowering: are the treatment guidelines still appropriate?
    Deslypere JP
    Int J Clin Pract; 2000 Jun; 54(5):307-13. PubMed ID: 10954957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
    Jacobson TA
    Ann Intern Med; 2000 Oct; 133(7):549-54. PubMed ID: 11015169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
    Eisenberg DA
    Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
    Allison TG; Squires RW; Johnson BD; Gau GT
    Mayo Clin Proc; 1999 May; 74(5):466-73. PubMed ID: 10319076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling risk and new therapeutic interventions: looking ahead.
    Shepherd J
    Am J Med; 1998 Feb; 104(2A):19S-22S. PubMed ID: 9550503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management.
    Pedersen TR
    Am J Cardiol; 2001 Mar; 87(5A):8B-12B. PubMed ID: 11256850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for treatment.
    Gotto AM
    Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation.
    Evans M; Rumberger JA; Azumano I; Napolitano JJ; Citrolo D; Kamiya T
    Vasc Health Risk Manag; 2014; 10():89-100. PubMed ID: 24600231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.